News

Amprius Technologies Addresses Recent NYSE Compliance Notice

Amprius Technologies Addresses Recent NYSE Compliance Notice

Challenges with NYSE Compliance for Amprius Technologies

Recently, Amprius Technologies, Inc. (NYSE: AMPX) received a notification from the New York Stock Exchange (NYSE) concerning its compliance with listing standards. This notice indicates that the company's common stock has fallen below the required average closing price of $1.00 over a 30-day trading span. It’s important to highlight that this notice points to a deficiency rather than an immediate delisting, meaning Amprius' shares will continue to trade on the NYSE while the company evaluates its options.

Grasping the NYSE Listing Rule

According to the NYSE Listing Rule, Amprius is required to take measures to rectify this deficiency. The company has a window of six months to restore compliance. This can be achieved if the stock price reaches at least $1.00 on the final trading day of any month, maintaining an average closing price of at least that amount for the following 30 trading days. This recent notice acts as a prompt for Amprius to rethink and adapt its market strategies efficiently.

Amprius Technologies' Focus on Compliance

Amprius Technologies is dedicated to maintaining its NYSE listing and is actively exploring various strategies to regain compliance. The company assures stakeholders that the NYSE's notice doesn’t present an immediate risk to its operations or its reporting obligations with the U.S. Securities and Exchange Commission (SEC). As Amprius moves ahead, its main priority remains to protect the interests of its shareholders and stakeholders.

Effect on Business Operations

This compliance notice has sparked discussions about its potential impact on Amprius' core business activities. Nevertheless, the company reassures its partners and customers that its business operations are strong and unaffected by this situation. Amprius remains committed to delivering high-quality lithium-ion batteries, evidenced by impressive performance metrics in energy density and efficiency.

About Amprius Technologies, Inc.

Amprius Technologies, Inc. is widely recognized for its expertise in producing high-energy and high-power lithium-ion batteries. The company boasts the highest energy density cells available in the industry, featuring SiMaxx™ batteries that achieve remarkable energy metrics of up to 450 Wh/kg and 1,150 Wh/L. In its efforts to broaden its product range, Amprius has also introduced the SiCore™ platform, further enhancing its ability to meet the diverse needs of its customers. With manufacturing and R&D facilities situated in Fremont, Amprius is positioned to maintain competitive advantages and drive growth within the battery sector.

Boosting Manufacturing Capabilities

To address growing customer demands, Amprius has secured agreements for over 500 MW/h of contract manufacturing capacity. Additionally, they’ve committed to building a gigawatt-hour-scale facility in Brighton, Colorado, which will greatly enhance their production capabilities. This strategic decision underscores the company's commitment to innovation and expansion in the market.

Looking Ahead

As Amprius faces this challenge from the NYSE, it will concentrate on regaining compliance while simultaneously developing cutting-edge battery technologies. Ongoing investments in research and development, along with strategic partnerships, align with the company's vision to lead the market in high-performance battery solutions.

Frequently Asked Questions

What is the current status of Amprius Technologies on the NYSE?

Amprius Technologies remains listed on the NYSE despite receiving a compliance notice. The company has a six-month period to rectify the deficiency.

How is Amprius planning to regain compliance with the NYSE?

The company aims to comply by ensuring its stock price exceeds $1.00 on the last trading day of any month within the specified six-month timeframe.

Will the compliance notice affect Amprius' business operations?

No, the compliance notice is not expected to influence Amprius Technologies' ongoing business operations or its reporting with the SEC.

What products does Amprius Technologies manufacture?

Amprius produces high-energy and high-power lithium-ion batteries, including its SiMaxx™ series and the newly launched SiCore™ batteries.

Where is the headquarters of Amprius Technologies located?

The corporate headquarters of Amprius Technologies is situated in Fremont, California, where they also have a manufacturing facility and R&D lab.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 8

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Growth of the Network API Market by 2030

Updated Category News Views 125

Network API Market Overview As technology evolves, the demand for Network APIs is accelerating, and projections show the market will grow from USD 1.96 billion to an impressive USD 6.13 billion by 2030, reflecting a compound annual growth rate (CAGR) of 25.7% during the forecast period. This surge signifies a shift in how businesses leverage APIs to enhance connectivity...

Continue Reading
Quebec City Real Estate Market Sees Strong Activity Surge

Updated Category News Views 179

Quebec City Real Estate Market Activity in August As summer comes to a close, the residential real estate market in Quebec City is experiencing notable activity, achieving the second highest sales levels in 25 years for this month. This trend highlights the remarkable resilience and ongoing demand in a market that continues to change. Sales Data Overview In August, the...

Continue Reading
Understanding Market Trends: Income Strategies with IQQQ ETF

Updated Category News Views 151

Navigating the Current Tech Market Dynamics This year, the Nasdaq Composite index has outperformed other major indices, showing a solid increase of more than 21%. This surge in technology stocks has, however, been volatile, with the index recently experiencing a dip of roughly 2%. Concerns around a potential bubble in artificial intelligence have contributed to this...

Continue Reading
Boussard & Gavaudan Holding Limited: Latest NAV Update

Updated Category News Views 272

Boussard & Gavaudan Holding Limited Overview Boussard & Gavaudan Holding Limited is a well-known closed-ended investment company recognized within the finance industry for its effective management strategies. This article provides recent updates on the company's net asset value (NAV) and market activities. Estimated NAV Information The Directors of Boussard & Gavaudan...

Continue Reading
Currency Insights: Dollar and Yen Dynamics Amid Changes

Updated Category News Views 153

Current Trends in Currency Markets The US dollar is maintaining its strength as holiday trading continues with low volumes, while US Treasury yields are gradually rising. Although the dollar remains resilient against various currencies, it has shown some weakness against the Japanese yen and Canadian dollar lately. Markets are keenly observing the impact of potential...

Continue Reading